Technology ID
TAB-3242
Regenerative Therapy for Cartilage Damage
E-Numbers
E-152-2017-0
Lead Inventor
Robey, Pamela (NIDCR)
Co-Inventors
Shirvan, Mitchell (Synerra Medical)
Gorodetsky, Rafael (Hadassah Medical Center)
Kuznetsov, Sergei (NIDCR)
Lazmi-Hailu, Astar (Hadassah Medical Center)
Applications
Therapeutics
Research Materials
Non-Medical Devices
Medical Devices
Diagnostics
Therapeutic Areas
Immunology
Geriatrics
Development Stages
Pre-Clinical (in vitro)
Lead IC
NIDCR
ICs
NIDCR
The subject technology discloses a tissue engineering method for treating cartilage damage. Stem cells from bone marrow are attached to a novel scaffold, hyaluronic acid-coated fibrin microbeads, and transferred to a live host to form cartilage. The regenerated cartilage is stable and not hypertrophic, which has been problematic in the current regenerative methods.
Commercial Applications
- A novel scaffold, hyaluronic acid-coated fibrin microbeads.
- Cartilage repair.
Competitive Advantages
- Coating with hyaluronic acid makes the fibrin microbeads more stable for mature cartilage formation.
- The new hyaline cartilage is stable and hypertrophy-resistant.
Licensing Contact: